| Literature DB >> 27769888 |
Maria Gregori1, Mark Taylor2, Elisa Salvati1, Francesca Re1, Simona Mancini1, Claudia Balducci3, Gianluigi Forloni3, Vanessa Zambelli1, Silvia Sesana1, Maria Michael2, Christos Michail2, Claire Tinker-Mill4, Oleg Kolosov4, Michael Sherer2, Stephen Harris5, Nigel J Fullwood2, Massimo Masserini1, David Allsop6.
Abstract
Aggregation of amyloid-β peptide (Aβ) is a key event in the pathogenesis of Alzheimer's disease (AD). We investigated the effects of nanoliposomes decorated with the retro-inverso peptide RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2) on the aggregation and toxicity of Aβ. Remarkably low concentrations of these peptide inhibitor nanoparticles (PINPs) were required to inhibit the formation of Aβ oligomers and fibrils in vitro, with 50% inhibition occurring at a molar ratio of ~1:2000 of liposome-bound RI-OR2-TAT to Aβ. PINPs also bound to Aβ with high affinity (Kd=13.2-50 nM), rescued SHSY-5Y cells from the toxic effect of pre-aggregated Aβ, crossed an in vitro blood-brain barrier model (hCMEC/D3 cell monolayer), entered the brains of C57 BL/6 mice, and protected against memory loss in APPSWE transgenic mice in a novel object recognition test. As the most potent aggregation inhibitor that we have tested so far, we propose to develop PINPs as a potential disease-modifying treatment for AD.Entities:
Keywords: Alzheimer's disease; Liposomes; Oligomer; Retro-inverso peptide; β-amyloid
Mesh:
Substances:
Year: 2016 PMID: 27769888 DOI: 10.1016/j.nano.2016.10.006
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307